Diagnosis of hereditary platelet disorders in the era of next-generation sequencing: “primum non nocere”

34Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Summary: Inherited platelet disorders can affect “only platelets”, occur as a “syndromic phenotype” or be associated with “increased risk of hematological malignancies”. Genetic testing is attractive for diagnosis of inherited platelet disorders. However, many physicians who refer patient blood for genetic testing are unaware of the association of certain inherited platelet disorders with other risks. Inherited platelet disorders associated with minor–moderate bleeding rarely cause patient distress. In contrast, identification of a mutation associated with an increased risk of leukemia may cause a major psychological disease burden, without offsetting the beneficial impact on management. Guidelines recommend postponing genetic testing “until the patient reaches adulthood or at least until the child is mature enough to participate in decision making”. In our opinion, outside research, (genetic) testing in children with inherited platelet disorders should only be performed if it influences management. In adults, genes causing inherited platelet disorders associated with an increased risk of hematological malignancies should only be tested after obtaining explicit informed consent.

Cite

CITATION STYLE

APA

Greinacher, A., & Eekels, J. J. M. (2019). Diagnosis of hereditary platelet disorders in the era of next-generation sequencing: “primum non nocere.” Journal of Thrombosis and Haemostasis, 17(3), 551–554. https://doi.org/10.1111/jth.14377

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free